Skip to main content Skip to footer

Colliers Completes New Headquarters Search for Rapidly-Growing Gene Therapy Firm Spirovant


PHILADELPHIA, PA, January 27, 2021Spirovant Sciences, a gene therapy company developing treatments and cures for genetic respiratory diseases including cystic fibrosis, has announced the leasing of its new, expanded headquarters and laboratories at uCity Square at 3675 Market Street. 


Joseph Fetterman and Clifford Brechner of the Colliers Life Sciences team led the search on Spirovant’s behalf, navigating a tightly constrained market for lab space to produce a creative solution for the firm within the robust gene and cell therapy epicenter of Philadelphia’s University City.

“In an environment where purpose-built lab space remains quite limited, Colliers and Wexford Science + Technology found that needle in a haystack - existing office space for lab conversion that enables Spirovant’s continued growth at 3675 Market Street. Colliers is pleased to have assisted Spirovant by delivering real estate solutions that matched its needs as the company grows and evolves.” noted team leader Joseph Fetterman.

In its recent market report, Converging for Cures, Colliers noted that with more than 750,000 square feet of current market demand for R&D lab and clinical scale manufacturing in the Philadelphia region, drug development companies are finding the lack of supply challenging. While the pipeline remains strong, delivery of over 1.5 million square feet of new lab space over the next two years will provide welcome relief for seekers of purpose-built lab and manufacturing space to support ongoing research and drug development.

For more information contact:
Joseph Fetterman, Executive Vice President  +1 215 928 7541




About Colliers International

Colliers International (NASDAQ, TSX: CIGI) is a leading global real estate services and investment management company. With operations in 68 countries, our 14,000 enterprising people work collaboratively to provide expert advice and services to maximize the value of property for real estate occupiers, owners and investors. For more than 20 years, our experienced leadership team, owning more than 40% of our equity, have delivered industry-leading investment returns for shareholders. In 2018, corporate revenues were $2.8 billion ($3.3 billion including affiliates), with more than $26 billion of assets under management. 
Learn more about how we accelerate success at, Twitter @Colliers or LinkedIn


Download PDF  |  View all Philadelphia News

Related Experts

Joseph Fetterman

Executive Vice President | Healthcare and Life Sciences


Joe joined Colliers International in 2012 to lead and grow Colliers’ Office Brokerage Division.  Today he focuses on providing strategic solutions to local, national and global Health Care, Life Sciences and Corporate clients. Joe’s background in architecture, real estate development and financial analysis provides clients with an experienced professional and strategic leader who integrates  complex factors to create successful results for clients

Joe is a Healthcare Fellow and serves on Colliers National Healthcare Services and Life Sciences Steering Committees. 

View expert

Clifford Brechner

Vice President


Clifford Brechner joined Colliers in 2019 to focus his talents in the fast-growing Philadelphia Life Sciences division. 

Clifford comes to Colliers with more than 35 years of experience leading companies with revenues in excess of $10 million. For the past 20 years Brechner has led ventures within the analytical laboratory and quality assurance industry, making him exceptionally suited to help laboratory clients navigate their complicated real estate needs in an ever-changing market. 

Clifford is a native of New York and currently resides in Bryn Mawr with his wife and two children. 


View expert